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Abstract
The aim of this study was to investigate the role of common polymorphisms in the NER pathway
genes in the tumorigenesis of osteosarcoma and in the response to DNA damaging therapies, such
as cisplatin-based neoadjuvant therapy. XPD (rs13181 and rs1799793), XPG (rs17655), and
ERCC1 (rs3212986 and rs11615) polymorphisms were analysed in a group of 130 homogenously-
treated patients with high-grade osteosarcoma for association with event free survival (EFS) using
Kaplan-Meier plots and log-rank test. A positive association was observed between both XPD
SNPs and an increased EFS (HR= 0.34, 95% CI 0.12-0.98 and HR= 0.19, 95% CI 0.05-0.77,
respectively). We had also performed a case-control study for relative risk to develop
osteosarcoma. Patients carrying at least one variant allele of XPD rs1799793 had a reduced risk of
developing osteosarcoma compared to wild type patients (OR=0.55, 95% CI 0.36-0.84).This study
suggests that XPD rs1799793 could be a marker of osteosarcoma associated with features
conferring either a better prognosis or a better outcome after platinum therapy, or both.
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INTRODUCTION
Osteosarcoma is the most common primary bone tumor occurring in children and
adolescents. It most often develops in periods of rapid skeletal growth with more than 50%
of tumors occurring in the long bones1.
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Neoadjuvant chemotherapy followed by definitive resection with subsequent adjuvant
chemotherapy is a well-established approach for the treatment of localized osteosarcoma
since chemotherapy can eradicate the micrometastatic disease that is believed to be present
in the majority of patients with clinically resectable cancer2;3. The neoadjuvant treatment of
osteosarcoma includes the administration of cisplatin in combination with doxorubicin,
methotrexate and ifosfamide1;4. This approach results in a 5-year survival rate of 60-70% for
patients with non-metastatic osteosarcoma of the extremities1;5.
The decision about the best treatment choice for these patients is still based upon the
traditional assessment of the tumor characteristics, and there are no molecular markers that
can guide therapy. The most consistent clinicopathologic prognostic markers are still
clinical, including the presence of metastases at diagnosis, the histological response of the
tumor to preoperative chemotherapy and tumor volume1;6;7. Among biological markers,
previous studies have identified various factors which appeared to be associated with poor
prognosis for patients with osteosarcoma, including overexpression of MDR1/P-
glycoprotein1;8, proliferation rate of tumor, P53 gene alteration and translocation9;10.
However, amelioration of the prognosis of osteosarcoma should involve molecular
approaches to offer patients additional, possibly tailored, therapies1;11;12.
It has been suggested that deficiencies in DNA repair capacity could have a role in cancer
onset or in its progression, as well as in affecting the response to DNA damaging
agents10;13;14. DNA repair processes involve at least four different pathways acting on
specific types of DNA damages. In particular, the nucleotide excision repair (NER) pathway
repairs bulky lesions and has been associated with tumor progression and response to
platinum-based chemotherapy15;16. Excision repair cross-complementing group 1 (ERCC1/
XPA), group 2 (ERCC2/XPD), group 4 (ERCC4/XPF) and group 5 (ERCC5/XPG) are
members of the NER pathway. It has been demonstrated that a deficiency of DNA repair
capacity of NER genes is related to the presence of single nucleotide polymorphisms (SNPs)
that result in altered mRNA expression or protein activity13. XPD 35931A>C (rs13181,
Lys751Gln) and 23591G>A (rs1799793, Asp312Asn), XPG 3507G>C (rs17655,
Asp1104His), ERCC1 8092C>A (rs3212986, Gln504Lys) and 19007C>T (rs11615,
Asn118Asn) are common in Caucasians and lead to reduced DNA repair capacity17-20. The
complex system of DNA repair plays a pivotal role in maintaining genomic integrity by
counteracting endogenous or exogenous insults that can lead to an increase in cancer
susceptibility. The main cytotoxic effect of cisplatin is due to the formation of mono or bi-
functional DNA adducts causing inter- or intra-strand cross linking being removed by the
NER pathway. A deficiency in the ability to repair DNA damages induced by platinum
agents could therefore alter the response to treatment.
Several studies have evaluated the role of genetic variants in the NER pathway as either
prognostic for survival or predictive for the efficacy of platinum-based
chemotherapy15;21-30. However, from these findings, no single NER gene variant emerges
as a validated marker with an effect that is consistently replicated across different studies.
The role of common variation in genes of the NER pathway has been also evaluated as risk
factors for epithelial cancer, and the results are contradictory, with predisposing
effect29;31-39 or protective effect40;41, whereas for mesenchimal tumors, like sarcomas, only
few studies have been published so far10;21;22.
In the present study, we have evaluated the effect of five NER gene SNPs for risk and
survival in 130 patients with high-grade primary osteosarcoma homogeneously treated with
neoadjuvant chemotherapy.
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One hundred and thirty patients with high grade intramedullary osteosarcoma of the
extremities, without prior treatment and with no evidence of metastasis at diagnosis, were
accrued from the Istituto Ortopedico Rizzoli, Bologna. The characteristics of these patients
are reported in Table 1. Patients were all treated with chemotherapy protocols including
cisplatin together with doxorubicin, methotrexate, and ifosfamide. The treatment regimens
were based on only two different protocols4: the IOR OS-N4 (cisplatin, doxorubicin, high
dose methotrexate, ifosfamide) or the IOR OS-N5 (cisplatin, doxorubicin, high-doses
methotrexate, high-doses ifosfamide).
Histological response to preoperative chemotherapy was defined on the basis of the
evaluation of tumor necrosis. A good histological response was considered when the extent
of tumor necrosis was 90% or greater4.
After the end of treatment, patients were checked by imaging (radiographs or CT) every 2
months for two years, every 3 months in the third year and then every 6 months. After the
fifth year, patients were checked annually with radiographs.
Median follow up was 38 months (range 1-278 months) from the time of diagnosis until
death by any cause. Event-free survival (EFS) was calculated from the first day of
preoperative chemotherapy to the most recent follow-up, local or systemic recurrence or
death by any cause (median EFS was 28 months, range 1-278). Patients who were alive at
the time of the last follow-up were censored at that time. Overall survival (OS) was
calculated from the time of diagnosis until death by any cause or last follow-up.
Two hundred and fifty healthy controls (subjects without cancer at the time of enrolment)
were recruited at the National Cancer Institute, Aviano, Italy, for the purpose of
investigating the DNA repair variants as potential markers of cancer risk. Controls were
matched for age and sex (median age 35 years, 156/101 males/females).
After signing an informed consent, blood (patients and controls) and non neoplastic (by
histology) muscular tissue (patients only) samples were collected and frozen at –80°C until
genetic analysis. Patients and controls are of Caucasian ethnicity. This study has been
approved by the Institutional Review Boards of the accruing centers.
Genotyping assays
The genomic DNA was extracted with the High Pure PCR Template Preparation Kit (Roche
Diagnostic GmbH, Mannheim, Germany). For XPD rs13181, XPD rs1799793 and XPG
rs17655 the genotyping assays were performed using pyrosequencing (Biotage, Uppsala,
Sweden) with specific 5’-biotinylated primers.
Amplification conditions were 35 cycles of 95°C for 30 seconds, each annealing temperature
for 30 seconds, and 72°C for 30 seconds. A final 10 minutes extension at 72°C completed
the amplification. Primer sequences and PCR conditions are described in the supplementary
table. The sequencing primers used for the analysis were developed using SNP Primer
Design software (version 1.0) from Biotage AB (Uppsala, Sweden).
ERCC1 rs3212986 and rs11615 were genotyped by TaqMan® pre-designed SNP
genotyping assays by Applied Biosystem (https://products.appliedbiosystems.com/). The
Applera TaqMan Genotyping Master Mix was employed together with the validated primers
and probes mix at the usage concentration as provided by the manufacturer.
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This study aims to identify the association between genetic variants and EFS. EFS was
chosen as the primary endpoint because of the difficulty to take into account the effects of
therapies administered after tumor recurrence. Additional analyses included the evaluation
of the association between genetic variants and OS, relapse rate, as well as the risk of
osteosarcoma using healthy controls in a case-control study.
Assuming alpha=0.05 and a statistical power of 0.8, the present sample size (N=130)
allowed to estimate HRs equal 0.55 or lower. The association with EFS and OS was
computed by Kaplan-Meier method42, and log-rank test was used to test the differences
between subgroups. Differences between subgroups were also tested in univariate analysis
using the Cox proportional hazards model43 to compute the hazard ratio (HR) and the
corresponding 95% confidence interval (CI). Covariates that were significant in the
univariate analysis were also tested in the multivariate model. As a final set, a Cox
proportional hazards model was fitted with interaction terms between some covariates. Chi-
squared analysis for trend was also evaluated.
Fisher's exact test44 was used for a three genotype test to investigate the role of
polymorphisms in histological response and in relative risk to develop osteosarcomas (allele
frequencies between patients and controls). Odds ratios (ORs) and their 95% CIs were
calculated.
The Hardy–Weinberg equilibrium was tested for each SNP, showing no significant
deviation (p>0.05). For all the analysis conducted in this study, a p<0.05 was used as the
cut-off for significance, not adjusted for multiple comparisons.
RESULTS
XPD rs13181 and rs1799793 are significantly associated with the EFS in univariate
analysis: the variant allele confers increased EFS, with evidence for a trend for a gene-
dosage effect (Table 2, Figures 1 and 2). Subjects carrying the homozygous mutated
genotype showed a protective risk for relapse compared to wild type genotype (HR=0.34,
95%CI 0.12-0.98, p-trend=0.04 for XPD rs13181 variant allele and HR=0.19, 95%CI
0.05-0.77, p-trend=0.002 for XPD rs1799793 variant allele). Testing the impact of having at
least one variant allele of these two SNPs, a correlation with EFS was confirmed for XPD
rs1799793 (23591G>A; GA+AA vs GG, HR=0.40, 95%CI 0.22-0.74, p-trend=0.004) but
not for XPD rs13181 (35931A>C; AC+CC vs AA, HR=0.65, 95%CI 0.38-1.10, p-
trend=0.11) (Table 2). Patient characteristics (i.e. gender, age, histological type of tumor or
necrosis at diagnosis) were not significant in the univariate analysis and were therefore not
used in the multivariate analysis.
In a multivariate analysis, considering both XPD variants, only the association between the
XPD rs1799793 and EFS remained significant (adjusted p-trend=0.01, Table 2). Patients
carrying the XPD rs1799793 variant allele (GA or AA) had a higher probability to be event
free compared to wild type patients (80% vs 40%, Table 2). In this patient population, most
relapse events occurred within five years. No association could be observed between EFS
and the other three SNPs of the NER genes ERCC1 and XPG (Table 2). Patient
characteristics (i.e. gender, age, histological type of tumor or necrosis at diagnosis) were not
significant in the univariate analysis of EFS and were not used in the multivariate analysis.
Combined analysis of both XPD polymorphisms on the influence of an increased variant
allele number on EFS revealed that none of the cases carrying two variant alleles (in total, 4
variant alleles) relapsed (Table 3 and Figure 3). The probability for EFS at 5 years was
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directly proportional to the number of variant alleles: patients with both homozygously
mutated genotype had a better prognosis with a null risk of relapse (p-value for trend 0.03).
The risk of relapse for patients with no variant allele was more than 3-fold higher than for
patients with 3-4 variant alleles (HR=0.29, 95%CI 0.10-0.84, p-value=0.003). Inspite of the
significant association between XPD rs1799793 and EFS, none of the five SNPs tested in
this study was significantly associated with OS (Table 4). None of the polymorphisms
analyzed was significantly associated with chemotherapy-induced necrosis as response to
preoperative treatment (data not shown).
When the NER pathway gene SNPs were investigated for differences in allele frequencies
between cases and controls, a significant association was observed for XPD rs1799793,
indicating that patients carrying at least one variant allele (GA+AA) had a decreased risk to
develop osteosarcoma compared to patients with no variant alleles (OR=0.55, 95% CI
0.36-0.84, Table 5). All the other SNPs did not show any association with the risk of
osteosarcoma.
DISCUSSION
Osteosarcoma, despite being the eighth most common cancer of childhood, is classified as a
“rare disease” representing 2.4% of all malignancies in pediatric patients and approximately
20% of all bone cancers45. Its incidence is about 400-500 cases per year in the United States,
800-1000 cases per year in Europe, and 100-120 cases per year in Italy1. Due to this rarity, it
is very difficult to perform large studies, particularly in patients who are homogeneously
treated in order to evaluate the possible clinical impact of the analyzed markers. In this
study, we were able to collect a series of 130 osteosarcoma patients, with primary high-
grade tumors located at the extremities, without metastasis at diagnosis, and all treated with
neoadjuvant chemotherapy based on the administration of cisplatin in association with
doxorubicin, high-dose methotrexate and ifosfamide.
The main finding of this study is that XPD rs13181 and rs1799793 are related to higher EFS
in osteosarcoma patients treated with neoadjuvant chemotherapy. The presence of at least
one of these alleles confers a protective role for relapse, with an HR of 0.34 and of 0.19 for
XPD rs13181 and XPD rs1799793, respectively. Moreover, the effect appears to be even
stronger after combining these two polymorphisms, as none of the seven homozygous
variant patients for both SNPs relapsed compared to 24 (58.5%) patients without any variant
allele after 60 months of follow up. However, considering that these two XPD SNPs are not
in linkage disequilibrium, the multivariate analysis including both SNPs is suggestive of
XPD rs1799793 being the main SNP driving these associations. The presence of a germline
polymorphism translated to a variation in the aminoacid codified (Gln to Lys for XPD
rs13181 and Asn to Asp for XPD rs1799793) reduces the repair capacity and can result into
greater efficacy of platinum treatment, due to increased DNA damage and increased
cytotoxic effect of platinum. In theory, patients with defective DNA repair should also be at
increased risk of toxicities. However, since we did not collect the toxicity data from these
patients this hypothesis cannot be verified in the present study.
In the current study, we found that the presence of XPD rs1799793 and XPD rs13181 could
provide a therapeutic advantage from cisplatin chemotherapy, probably by reducing DNA
repair activity. These results are in agreement with those reported for other cancers22,26,28,30
where XPD variant alleles (rs13181 and rs1799793) were associated with a better clinical
outcome after cisplatin therapy. Recently, Caronia et al. reported conflicting results on the
role of XPD rs13181 in a small set of osteosarcoma patients21. It must be highlighted that
the patients from Caronia study had different characteristics from our series. They
considered also metastatic patients at diagnosis and neoadjuvant chemotherapy not included
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cisplatin. However, this discrepancy requires further studies in a larger and homogeneous
group of OS patients to better clarify the prognostic role of XPD rs13181.
Our data are suggestive of a predictive role of these two XPD polymorphisms, both alone or
in combination, for patients who underwent platinum-based neoadjuvant treatment.
However, due to the lack of a control group of patients who did not receive chemotherapy,
our single-cohort study cannot ascertain their predictive role for platinum-mediated
response. In addition, the significant improvement in EFS of XPD polymorphisms was not
translated into longer OS, possibly because we were not able to take into account the effect
of additional therapies given after recurrence or for a weak median follow-up time (3 years).
In this study, we also provide information of the effect of these SNPs as determinants of
osteosarcoma development risk. Our results indicated that the XPD rs1799793 conferred a
reduced risk of about 2-fold to develop osteosarcoma. Two other studies (one in soft tissue
sarcomas (STS) and one in osteosarcoma) were not able to detect an effect of XPD
rs179979310;46. In particular, Nakayama et al.46 did not find significant associations
between 50 missense SNPs of DNA repair genes (including the XPD SNPs of our study) and
the susceptibility to bone sarcomas and STS. The difference with our results could be
explained by the absence of a histologic stratification of patients and ethnic differences
between the two patient populations. In other tumor types, the results are discordant with
XPD rs1799793 being either a protective (for cervical47 and breast cancer48) or a
predisposing SNP (for lung49;50, gastric51 and prostate cancers52). The recent experience
with genome-wide association studies (GWAS) of cancer risk are suggestive of the
involvement of multiple SNPs53-55, each of them conferring a marginal effect on the risk. In
light of the controversial results on XPD, genetic determinants of osteosarcoma risk remain
to be discovered through GWAS.
For osteosarcoma patients, neoadjuvant treatment including cisplatin represents a strategy to
lead to a reduction of limb amputation and to an improvement of survival. Unfortunately,
despite the positive clinical results obtained with neoadjuvant treatments, there is still a
significant proportion of patients who show a partial or very low response to conventional
regimens 1. The identification of genetic markers, which have prognostic value or are
predictive of neoadjuvant chemotherapy response, would represent an important tool to
reach informed decisions on how to select the subgroup of osteosarcoma patients who are
likely to benefit from a more specific, tailored treatment11. Based on the results of our study,
we propose that XPD rs1799793 is a germline variant to be subsequently tested
prospectively in patients with high-grade osteosarcoma. This SNP might be a potential
marker for a subset of osteosarcoma with hitherto unknown molecular features associated
with a better prognosis after platinum-based therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Grants:
This study was supported by grants from: Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) grants to
M.Serra; EuroBoNeT, an European Commission-granted Network of Excellence for studying the pathology and
genetics of bone tumors (LSHC-CT-2006-018814); Italian Ministry of Health “Progetto Oncologia”
Biason et al. Page 6














1. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma.
Expert Opin Emerg Drugs. 2010; 15(4):615–634. [PubMed: 20690888]
2. Bruland OS, Hoifodt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in
osteosarcoma patients. Clin Cancer Res. 2005; 11(13):4666–4673. [PubMed: 16000559]
3. Wesolowski R, Budd GT. Use of chemotherapy for patients with bone and soft-tissue sarcomas.
Cleve Clin J Med. 2010; 77(Suppl 1):S23–S26. [PubMed: 20179184]
4. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant
chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur
J Cancer. 2005; 41(18):2836–2845. [PubMed: 16298125]
5. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric
osteosarcoma. Oncologist. 2004; 9(4):422–441. [PubMed: 15266096]
6. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma
of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated
at a single institution. Cancer. 2006; 106(5):1154–1161. [PubMed: 16421923]
7. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in
osteosarcoma. J Cancer Res Clin Oncol. 2008; 134(3):281–297. [PubMed: 17965883]
8. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, et al. Value of P-glycoprotein
and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of
the extremities. J Clin Oncol. 2003; 21(3):536–542. [PubMed: 12560446]
9. Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA, et al. VEGF expression as a
prognostic marker in osteosarcoma. Pediatr Blood Cancer. 2009; 53(6):1035–1039. [PubMed:
19621435]
10. Le M, V, Longy M, Bonaiti-Pellie C, Bui B, Houede N, Coindre JM, et al. Genetic polymorphisms
of the XPG and XPD nucleotide excision repair genes in sarcoma patients. Int J Cancer. 2006;
119(7):1732–1735. [PubMed: 16646069]
11. Kong C, Hansen MF. Biomarkers in Osteosarcoma. Expert Opin Med Diagn. 2009; 3(1):13–23.
[PubMed: 20574545]
12. Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, et al. Genomic alterations
and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res. 2010;
16(16):4256–4267. [PubMed: 20610556]
13. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with
cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1513–1530. [PubMed: 12496039]
14. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin
Cancer Res. 2008; 14(5):1291–1295. [PubMed: 18316546]
15. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer
chemotherapy. Cancer Treat Rev. 1998; 24(5):331–344. [PubMed: 9861196]
16. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, et al. A multivariate analysis of
genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination
chemotherapy in refractory colorectal cancer. Br J Cancer. 2004; 91(2):344–354. [PubMed:
15213713]
17. Benhamou S, Sarasin A. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am
J Epidemiol. 2005; 161(1):1–14. [PubMed: 15615908]
18. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, et al. Polymorphisms in the
DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood
mononuclear cells. Carcinogenesis. 2000; 21(5):965–971. [PubMed: 10783319]
19. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, et al. XPD
polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000; 21(4):551–555.
[PubMed: 10753184]
20. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision
repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001; 61(4):1354–
1357. [PubMed: 11245433]
Biason et al. Page 7













21. Caronia D, Patino-Garcia A, Milne RL, Zalacain-Diez M, Pita G, Alonso MR, et al. Common
variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome
in osteosarcoma patients. Pharmacogenomics J. 2009; 9(5):347–353. [PubMed: 19434073]
22. De las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al.
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-
small-cell lung cancer patients. Ann Oncol. 2006; 17(4):668–675. [PubMed: 16407418]
23. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic
polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with
platinum chemotherapy. J Clin Oncol. 2004; 22(13):2594–2601. [PubMed: 15173214]
24. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, et al. Genetic polymorphisms
affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum
compounds: a Korean population-based study. Gynecol Oncol. 2009; 113(2):264–269. [PubMed:
19203783]
25. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, et al. Relationship between
ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group
Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial
ovarian cancer. J Clin Oncol. 2008; 26(21):3598–3606. [PubMed: 18640939]
26. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, et al. DNA-repair
gene polymorphisms predict favorable clinical outcome among patients with advanced squamous
cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin
Oncol. 2006; 24(26):4333–4339. [PubMed: 16896002]
27. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide excision repair
pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control. 2003;
10(4):297–305. [PubMed: 12915808]
28. Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, et al. Single nucleotide
polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder
cancer patients treated with chemoradiotherapy. Br J Cancer. 2006; 95(5):561–570. [PubMed:
16880786]
29. Saldivar JS, Wu X, Follen M, Gershenson D. Nucleotide excision repair pathway review I:
implications in ovarian cancer and platinum sensitivity. Gynecol Oncol. 2007; 107(Suppl 1):S56–
S71. [PubMed: 17884153]
30. Bradbury PA, Kulke MH, Rebecca SH, Zhou W, Ma C, Xu W, et al. Cisplatin pharmacogenetics,
DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenetics and Genomics.
2009; 19(8):613–625. [PubMed: 19620936]
31. Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B, et al. The XPD variant alleles are
associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis. 2002;
23(4):599–603. [PubMed: 11960912]
32. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and
lung cancer risk: a meta-analysis. Int J Med Sci. 2007; 4(2):59–71. [PubMed: 17299578]
33. Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S, et al. DNA repair
polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2006; 27(5):
997–1007. [PubMed: 16308313]
34. Terry MB, Gammon MD, Zhang FF, Eng SM, Sagiv SK, Paykin AB, et al. Polymorphism in the
DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and
breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2004; 13(12):2053–2058. [PubMed:
15598760]
35. Vogel U, Hedayati M, Dybdahl M, Grossman L, Nexo BA. Polymorphisms of the DNA repair
gene XPD: correlations with risk of basal cell carcinoma revisited. Carcinogenesis. 2001; 22(6):
899–904. [PubMed: 11375896]
36. Vogel U, Laros I, Jacobsen NR, Thomsen BL, Bak H, Olsen A, et al. Two regions in chromosome
19q13.2-3 are associated with risk of lung cancer. Mutat Res. 2004; 546(1-2):65–74. [PubMed:
14757194]
Biason et al. Page 8













37. Wen H, Ding Q, Fang ZJ, Xia GW, Fang J. Population study of genetic polymorphisms and
superficial bladder cancer risk in Han-Chinese smokers in Shanghai. Int Urol Nephrol. 2009;
41(4):855–864. [PubMed: 19350405]
38. Yu HP, Wang XL, Sun X, Su YH, Wang YJ, Lu B, et al. Polymorphisms in the DNA repair gene
XPD and susceptibility to esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 2004;
154(1):10–15. [PubMed: 15381366]
39. Zhou W, Liu G, Park S, Wang Z, Wain JC, Lynch TJ, et al. Gene-smoking interaction associations
for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev.
2005; 14(2):491–496. [PubMed: 15734977]
40. Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, et al. Polymorphisms in MGMT
and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer. 2008; 123(1):
174–180. [PubMed: 18386788]
41. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of
DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006; 27(3):560–567.
[PubMed: 16195237]
42. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc.
1958; 53:457–481.
43. Cox DR. Regression models and life tables. J Roy Stat Soc B. 1972; 34:187–220.
44. Armitage, P.; Berry, G.; Matthews, JNS. Statistical Methods in Medical Res. 4th ed.. Blackwell
Science; Oxford: 2002.
45. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152:3–13.
[PubMed: 20213383]
46. Nakayama R, Sato Y, Masutani M, Ogino H, Nakatani F, Chuman H, et al. Association of a
missense single nucleotide polymorphism, Cys1367Arg of the WRN gene, with the risk of bone
and soft tissue sarcomas in Japan. Cancer Sci. 2008; 99(2):333–339. [PubMed: 18271933]
47. He X, Ye F, Zhang J, Cheng Q, Shen J, Chen H. Susceptibility of XRCC3, XPD, and XPG genetic
variants to cervical carcinoma. Pathobiology. 2008; 75(6):356–363. [PubMed: 19096231]
48. Jiang Z, Li C, Xu Y, Cai S, Wang X. Associations between XPD polymorphisms and risk of breast
cancer: a meta-analysis. Breast Cancer Res Treat. 2010; 123(1):203–212. [PubMed: 20111903]
49. Wang F, Chang D, Hu FL, Sui H, Han B, Li DD, et al. DNA repair gene XPD polymorphisms and
cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev.
2008; 17(3):507–517. [PubMed: 18349268]
50. Zhang J, Qiu LX, Leaw SJ, Hu XC, Chang JH. The association between XPD Asp312Asn
polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects. Med Oncol. 2010
epub ahead of print 30 November 2010; doi:10.1007/s12032-010-9501-8.
51. Zhang CZ, Chen ZP, Xu CQ, Ning T, Li DP, Hou RP. Correlation of XPD gene with susceptibility
to gastric cancer. Ai Zheng. 2009; 28(11):1163–1167. [PubMed: 19895736]
52. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS. DNA repair gene XRCC1 and
XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13(1):
23–29. [PubMed: 14744728]
53. Stadler ZK, Gallagher DJ, Thom P, Offit K. Genome-wide association studies of cancer: principles
and potential utility. Oncology. 2010; 24(7):629–637. [PubMed: 20669800]
54. Stadler ZK, Thom P, Robson ME, Weitzel JN, Kauff ND, Hurley KE, et al. Genome-wide
association studies of cancer. J Clin Oncol. 2010; 28(27):4255–4267. [PubMed: 20585100]
55. Wu MC, Kraft P, Epstein MP, Taylor DM, Chanock SJ, Hunter DJ, et al. Powerful SNP-set
analysis for case-control genome-wide association studies. Am J Hum Genet. 2010; 86(6):929–
942. [PubMed: 20560208]
Biason et al. Page 9
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Biason et al. Page 10














XPD 23591G>A (rs1799793) genotype curve's: ___GG vs. _ _GA vs. __ _ __AA
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The curves represent the increased number of variant alleles for combination of XPD
rs13181 and XPD rs1799793: ____ N=O (none variant alleles), __ __ __ N=1 (one variant
allele of XPD rs13181 or XPD rs1799793), __ _ __ N=2 (two variant alleles among XPD
rs13181 and/or XPD rs1799793), ____ _ ____N=3 (three variant alleles among XPD
rs13181 and/or XPD rs1799793), _ _ _ _N=4 (all four variant alleles).
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Table 1
Clinicopathologic characteristics of 130 osteosarcoma patients treated with neoadjuvant chemotherapy.
N (%)




Stage I-II 130 (100%)
III-IV 0 (0%)
Site Extremities 124 (95.4%)
Other 6 (4.6%)
Histological Type Osteoblastic 93 (71.6%)
Non-osteoblastic 34 (26.1%)
Not specified 3 (2.3%)
Surgical margins Wide 121 (93.1%)
Marginal 3 (2.3%)
Radical 6 (4.6%)
Necrosis ≥ 90% 59 (45.4%)
< 90% 71 (55.6%)




Cisplatin, doxorubicin, high dose methotrexate, ifosfamide 10 (7.7%)
Cisplatin, doxorubicin, high dose methotrexate 4 (3.1%)
N=number of patients
*
IOR OS-N4 (Cisplatin, doxorubicin, high dose methotrexate, ifosfamide)
**
IOR OS-N5 (Cisplatin, doxorubicin, high dose methotrexate, high dose ifosfamide)





















































































































































































































































































































































































































































































































































































































































































































































































































































Biason et al. Page 16
Table 3
Distribution of relapses, probability for event free survival (EFS) at 5 years, hazard ratio (HR) for relapse and
corresponding 95% confidence intervals (95% CI) according to combined XPD rs13181 and rs1799793.
N. of variant
alleles















1 19/38 (51.3%) 45% 0.87 (0.48-1.59)
2 10/33 (30.3%) 65% 0.43 (0.20-0.91)
3 4/11 (36.4%) 70% 0.29 (0.10-0.84)
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Table 4
Distribution of death, probability for overall survival (OS) at 5 years, hazard ratio (HR) for death and
corresponding 95% confidence intervals (95% CI) according to DNA repair genes polymorphism.
SNP Relapse Rate Probability to be alive at 5 years
p-value
** Univariate analysis
N. Death/N. Total (%)
p-value
* HR (95% CI)
p-trend
***








AC 13/64 (20.3%) 72% 0.73 (0.33-1.61)
CC 2/17 (11.7%) 88% 0.41 (0.09-1.83)







GA 5/38 (13.5%) 85% 0.50 (0.19-1.34)
AA 2/15 (13.3%) 69% 0.48 (0.11-2.05)







CA 12/44 (27.3%) 67% 0.86 (0.48-1.55)
AA 2/8 (25.0%) 69% 1.78 (0.69-4.58)







TC 9/59 (15.2%) 80% 0.71 (0.28-1.85)
CC 9/30 (30.0%) 62% 1.31 (0.51-3.40)







GC 6/39 (15.4%) 77% 0.72 (0.28-1.84)
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Table 5
Distribution of genetic frequencies of DNA repair SNPs in osteosarcoma cases and controls, Odd Ratio (OR)
for cancer risk and corresponding 95% confidence intervals (95% CI).
SNP Cases N. (%) Controls N. (%)
p-value
* OR (95% CI)
XPD rs13181 (35931 A>C)




    AC 64 (49%) 116 (46%) 1.05 (0.66-1.66)
    CC 17 (13%) 41 (16%) 0.79 (0.40-1.52)
        AC+CC 81 (62%) 157 (63%) 1.00 0.98 (0.63-1.52)
XPD rs1799793 (23591 G>A)




    GA 38 (28%) 100 (40%) 0.54 (0.33-0.87)
    AA 15 (13%) 38 (15%) 0.57 (0.29-1.17)
        GA+AA 52 (41%) 138 (55%) 0.007 0.55 (0.36-0.84)
ERCC1 rs3212986 (8092 C>A)




    CA 44 (35%) 98 (39%) 0.80 (0.51-1.27)
    AA 8 (7%) 23 (9%) 0.62 (0.26-1.46)
        CA+AA 52 (42%) 121 (48%) 0.27 0.77 (0.50-1.19)
ERCC1 rs11615 (19007 T>C)




    TC 59 (47%) 111 (45%) 1.23 (0.75-2.03)
    CC 30 (24%) 53 (21%) 1.32 (0.73-2.38)
        TC+CC 89 (71%) 164 (66%) 0.35 1.261 (0.79-2.01)
XPG rs17655 (3507 G>C)




    GC 39 (30%) 94 (38%) 0.78 (0.49-1.25)
    CC 16 (12%) 15 (6%) 2.01 (0.94-4.28)
        GC+CC 55 (42%) 109 (44%) 0.8 0.95 (0.62-1.46)
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